KLK3 and posterior cortical atrophy: The risk of recurrence after curative management of PCa primarily depends on the disease stage at initial diagnosis, which is typically determined by clinical Tumor, Node, and Metastasis (TNM) staging, PSA levels, and biopsy Gleason Score (GS) [2].